slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain PowerPoint Presentation
Download Presentation
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain

Loading in 2 Seconds...

play fullscreen
1 / 23

Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain - PowerPoint PPT Presentation


  • 104 Views
  • Uploaded on

Barriers and Challenges in Rare Diseases Research Centre for Biomedical Network Research on Rare Diseases (CIBERER) A model of cooperative and translational research on rare diseases. Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain. Dublin

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain' - nyoko


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Barriers and Challenges in Rare Diseases Research

Centre for Biomedical Network Research on Rare Diseases (CIBERER)A model of cooperative and translational research on rare diseases

Dr. José M. Millán, PhD

Deputy Director of CIBERER

Universitary Hospital La Fe, Valencia, Spain

Dublin

March 26, 2012

slide2

Research in Rare Diseases in Spain Historial Overview

  • 1996. Creation of CISAT (Centre fortheResearch of theToxicOil) in theInstitute of Health Carlos III (ISCIII)
  • 2000. RareDiseases are includedby ISCIII as a MainTopicforitsResearchProgramme.
  • 2001. CISAT becomes CISATER (Centre fortheResearch of theToxicOil and RareDiseases). Creation of SIERE (Service of InformationonRareDiseases in Spanish).
  • 2003. RETICs (Networks forThematicResearch): REpIER, INERGEN y RECGEN (Oneepidemiologicalnetwork and twogeneticresearchnetworkson RD. CISATER isthennamed IIER (InstituteforResearch in RareDiseases
  • 2006. CIBERER (Centre for Biomedical Network Research on Rare Diseases)
slide3

PrioritaryBiomedicalResearchTopics

  • CNIO: National Centre forOncologyResearch
  • CNIC: National Centre for Cardiovascular Research
  • CIBERS:
    • CIBERNED: Neurodegenerative disorders
    • CIBERES: Respiratory disorders
    • CIBERHED: Hepatic and digestive disorders
    • CIBEROBN: Obesity and Nutrition
    • CIBERDEM: Diabetes and associated metabolic disorders
    • CIBERBBN: Bioengineering, Biomaterials and Nanomedicine
    • CIBERER: Rare Diseases
    • CIBERESP: Epidemiology and Public Health
    • CIBERSAM: Mental Health
slide4

2009. StrategyforRareDiseases of theNationalHealthSystemMinistry of Health and Social Policy

Coordinator: Prof. Francesc Palau

  • Needs:
  • Information
  • Prevention and Early Diagnosis
  • Health and Social Care
  • Therapy
  • Research
  • Training
slide5

Barriers in Rare Diseases Research

Epidemiology

  • Lack of knowledge, lack of information
  • Deficientorinexistenthealthregistriesformanyrarediseases and difficultcodingaccordingtothe ICD system of classification
  • Difficultiesforepidemiologicalstudies
  • Visibility
  • Toidentifythecurrenthuman and informationresources
  • To set up registriesforeachraredisease and forrarediseases as a global problem
  • Toascertainthemedical/ economicalburden of rarediseases
  • Beware of Dr. !!
slide6

Barriers in Rare Diseases Research

Basic and ClinicalResearch

Natural History, Physiopathology, Genetics, DiseaseModels...

  • Thebudgetforbiomedicalresearchin Spainislowcomparedtoother EU countries (0.9% GDP)
  • Thebudgetforrarediseasesislowcomparedtocommondiseases
  • Tostimulatefuture R&D projectswithintheHealthStrategicActions
  • Topromotethepriorization of researchprojectsonrarediseases
  • Tocreate, maintain and improvenecessarystructures, facilities and humanresources
slide7

Barriers in Rare Diseases Research

Therapy

  • Lack of interest of thePharmaindustry (toomuchinvestmentfortooloweconomicalbenefit)
  • Veryfewemergingsmallcompaniesinterested in
  • Notmanylaboratoriesworking in therapiesforrarediseases
  • Topromoteinterest and financialsupportfromthePublicHealthSystem and Pharmaenterprises
  • CollaborationwithPharmaIndustry and Biotechs
  • Topromoteresearch in orphandrugs - advancedtherapies (gene-basedtherapy and celltherapy)
slide8

Barriers in Rare Diseases Research

Training

  • In Spainthereisnot a formal specialtyin ClinicalGenetics
  • Rarediseases are not a topic in Universities, Medicine Schools...
  • Students and scientist are more pronetocommondiseases (Cancer, AIDS, Alzheimer dis., Cardiovascular dis...)
  • Difficulties in making a carrier in genetics and rarediseases
  • Creation of thespecialtyin ClinicalGenetics (forphysicians, biomedicalsciences, psicology...(AEGH and CIBERER)
  • Courses, masters, academictopicsdevotedtorarediseases
why research on rare diseases is needed
Why research on rare diseases is needed?
  • Social reasons
  • Medical reasons
  • Scientific reasons
slide10

National Centres of Expertise (CoE)

  • Clinical investigation/Basic research
  • National research networks
  • Databases, registries, biobanks,
  • epidemiological surveillance
  • Pharmaceuticals and biotechs

Multidisciplinary and

Integrative approach

Rare Diseases Research

Supranational

collaboration

  • European Networks of CoE, ECN
  • European policy: fostering
  • national plans
  • European platforms & infrastructures
  • Patient empowerment

CIBERER: An integrative proposal

Human

factor

Financial

factor

Training

factor

Research groups

Society

Healthcare

system

Social

factor

Political

factor

slide11

Centre for Biomedical Network Research on Rare Diseases (CIBERER)

CIBERER is a public consortium set up at the initiative of the Institute of Health Carlos III (ISCIII) to act as a reference to coordinate and foster research into Rare Diseases in Spain.

CIBERER groups clinical and basic researchers promoting Cooperative Research. The knowledge generated is translated from the laboratory to clinical practice, and vice versa: Translational Research.

CIBERER provides strategic coordination, human resources and materials as well as a collaborative environment where synergy proper to high multidisciplinary and complementary research potential can be developed.

The CIBERER has large human resources - over 700 persons, made up of its own staff of 159 CIBERER contracted researchers, the rest of the members of the groups being scientists and technicians attached to CIBERER.

53% of ourpersonnel are

PhDassociateresearchers.

organization chart of the ciberer
Organization Chart of the CIBERER

Governing Board

External Advisory Scientific Committee

Permanent Commission

Scientific Director

ManagementCommittee

(Coordinators)

Management Office

Associated Clinical Groups

ResearchProgrammes: ThematicMedicalProgrammes

Paediatric and Developmental Medicine

Neuro-sensorial

Pathology

Inherited Cancer and Related Syndromes

Genetic Medicine

InheritedMetabolic Medicine

Mitochondrial Medicine

Endocrine Medicine

Intramural Biomedical Projects in Rare Diseases (PIBER)

Intramural Projects and Support Platforms

Support Platforms for Research into Rare Diseases (PITER)

slide13

Cooperative research in the field of rare diseases

CIBERER units are organized into seven Research Programmes:

slide14

Internal Structure of CIBERER

    • 60 Research Groups 29 Consorted Institutions 7 Research Programmes
    • The centre encloses clinical and basic researchers promoting Cooperative Research in Rare Diseases.
  • It is a Centre with an innovative network structure: offers opportunities of research actions and public-private collaboration.
  • The knowledge generated is translated from the laboratory to clinical practice
  • Translational Research
slide15

Cooperative research in the field of rare diseases

  • During its 5 years of existence, the CIBERER has allowed increasing the research capacity of its scientific groups and has increased the knowledge about Rare Diseases. CIBERER Programmes have:
  • Joined and increased the Cooperation between basic and clinical units
  • Increased the Research on Rare Diseases
  • Fostered the Participationof groups in the CIBERER’s programmes
  • Established Institutional Relations
  • Promotedand Disseminated the activities of groups
  • Fostered the International Cooperation opportunities of groups

BIER

BioInformatica de Enfermedades Raras

Network core facilities

slide16

CIBERER´s therapeutic research

  • Examples of intramural cooperative research projects
      • Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Raya et al. CIBERER Units 710 & 745. Nature. 2009 May 31
      • Transplantation of histocompatible allogeneic epidermal stem cells: Development of an effective clinical resource for patients with dystrophic epidermolysis bullosa.
      • INTRA/08/714,1.
      • Gene therapy in Dyskeratosis congenita
      • INTRA/08/757,1. CIBERER Units 757 & 710
      • Evaluation of the immune response and oxidative stress in patients affected by Gaucher disease subjected to different forms of therapeutic treatment.
      • INTRA/08/752.2. CIBERER Units 752 & 719

Cooperation with the Spanish Biotech Stakeholders Association (ASEBIO)

Collaboration with specific preclinical research actors

Agreement with Medina Foundation: non-profit public–private partnership between Merck Sharp and Dohme and public institutions focused on the discovery of new compounds and innovative therapies for unmet medical needs

CIBERER member of Innovative Medicaments working group

slide17

Experimental models in rare diseases: towards preclinical research

  • The approach is to establish scientific collaborations with experts from others academic research groups, biotech and pharmaceutical companies interested in testing their compounds and their panels of target screens in specific rare diseases models.
  • CIBERER experimental models network resources:
  • 91 animal models for the study of rare diseases:
  • Mouse, Zebrafish, Drosophila, Medaka, C. elegans.
  • 59 cells models for the study of rare diseases:
  • HeLa, 3T3, SH-S5SY neuroblastoma cells, fibroblasts, COS cells, lymphoblast cells, astrocytes…
  • Example of animal models:
  • McArdledisease (Pygm)
  • X-linkedadrenoleukodystrophy (Abcd1)
  • Charcot-Marie-Toothtype 4A (Gdap1)
  • Retinitis pigmentosa(Cerkl)
  • Down syndrome(Dyrk1a, others)
  • Laforadisease(malin, laforine)
  • Etc.
2007 2011 an increase of the scientific collaboration and productivity by the ciberer groups
2007 -2011: an increase of the scientific collaboration and productivity by the CIBERER groups

Evolution of intramural collaboration - CIBERER

2000-02 and 2006-08

slide19

2007 -2011: an increase of the scientific collaboration and productivity by the CIBERER groups

Intramural collaboration – CIBERER 2010

slide20

2007 -2011: an increase of the scientific collaboration and productivity by the CIBERER groups

Collaborative network of CIBERER groups with other Spanish institutions (240)

Collaborative network of CIBERER groups with other international institutions

(742)

slide22

Outcomes: increase on the number and quality of papers in RD

Evolution of the papers distribution of CIBERER groups based on JIF (Journal Impact Factor) parameters

slide23

“A model of Cooperative Research on Rare Diseases”

GoraibhmaithagatThankyou

More Information:

www.ciberer.es

info@ciberer.es

(+34) 96.339.47.89